|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
CA2128511C
(en)
|
1992-01-23 |
2006-11-07 |
Andreas Pluckthun |
Monomeric and dimeric antibody-fragment fusion proteins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
GB9720054D0
(en)
|
1997-09-19 |
1997-11-19 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9824437D0
(en)
|
1998-11-06 |
1999-01-06 |
Ylo Herttuala Seppo |
Gene therapy
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
NZ540194A
(en)
|
2002-11-08 |
2008-07-31 |
Ablynx Nv |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
PT1644412E
(pt)
|
2003-07-01 |
2015-12-23 |
Ucb Biopharma Sprl |
Fragmentos de anticorpos fab modificados
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
WO2005049094A1
(en)
|
2003-11-13 |
2005-06-02 |
Advantagene, Inc. |
A mixed complementary viral vector for gene therapy
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
CA2591813A1
(en)
|
2004-12-21 |
2006-06-29 |
Centocor, Inc. |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
TW201242976A
(en)
|
2011-01-07 |
2012-11-01 |
Abbott Lab |
Anti-IL-12/IL-23 antibodies and uses thereof
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
MX385344B
(es)
|
2012-11-28 |
2025-03-18 |
Zymeworks Bc Inc |
Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
US20170216387A1
(en)
|
2014-08-01 |
2017-08-03 |
Illycaffe' S.P.A. |
Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
PL3368572T5
(pl)
|
2015-10-02 |
2026-07-20 |
Les Laboratoires Servier |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
AU2016334401A1
(en)
*
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
PL3964529T3
(pl)
|
2016-01-22 |
2025-10-27 |
MabQuest SA |
Nieblokujące przeciwciała specyficzne względem pd1
|
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
|
EP3511340B1
(en)
|
2016-08-10 |
2024-10-02 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
|
|
US11390676B2
(en)
|
2016-10-13 |
2022-07-19 |
Symphogen A/S |
Anti-LAG-3 antibodies and compositions
|
|
CN110234355B
(zh)
|
2017-02-01 |
2021-11-09 |
浙江时迈药业有限公司 |
单体人IgG1 Fc和双特异性抗体
|
|
IL299348B2
(en)
|
2017-06-28 |
2025-05-01 |
Regeneron Pharma |
Antigen-binding proteins against human papillomavirus and methods of using them
|
|
CN110396133B
(zh)
|
2018-04-25 |
2021-07-23 |
免疫靶向有限公司 |
一种以白介素12为活性成分的融合蛋白型药物前体
|
|
WO2019222296A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
WO2020047067A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
EP3766512A1
(en)
|
2019-07-16 |
2021-01-20 |
Universität Zürich |
Fc-modified il-12 for local cns delivery
|
|
AU2020316002B2
(en)
|
2019-07-25 |
2026-05-07 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|
|
WO2021062406A1
(en)
*
|
2019-09-28 |
2021-04-01 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
MX2022011676A
(es)
|
2020-03-23 |
2023-03-08 |
Zymeworks Bc Inc |
Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
|
|
BR112022019708A2
(pt)
|
2020-04-01 |
2022-12-20 |
Xilio Dev Inc |
Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
|
|
JP7851612B2
(ja)
*
|
2020-04-17 |
2026-04-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
改変ｉｌ－１２及びｉｌ－２３ポリペプチドとその使用
|
|
US20250051413A1
(en)
|
2021-01-12 |
2025-02-13 |
Askgene Pharma Inc. |
Chimeric molecules comprising il-12 agonist polypeptide
|
|
US20240228586A1
(en)
|
2021-05-07 |
2024-07-11 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|
|
AU2022314734A1
(en)
*
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|